Prelude Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Prelude Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,500	Closed	-$23K	–	2105
2018 Q1	$23K	Buy	+2,500	New	+$13.8K	﹤0.01%	1244
2015 Q2	–	Sell	-5,000	Closed	-$31K	–	2227
2015 Q1	$31K	Buy	5,000 +2,500	+100%	+$14.4K	﹤0.01%	1658
2014 Q4	$16K	Buy	+2,500	New	+$15.2K	﹤0.01%	1768
2014 Q2	–	Sell	-2,000	Closed	-$48K	–	2293
2014 Q1	$48K	Sell	2,000 -3,800	-66%	-$55.1K	0.01%	1328
2013 Q4	$62K	Buy	+5,800	New	+$64K	0.01%	995

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Prelude Capital Management's ECYT Position: Q4 2018 in Review

Prelude Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 44,284 shares — an estimated $786K sold.

Prelude Capital Management first reported a position in ECYT in Q1 2014 and held it in 11 quarters. The position peaked at $786K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Prelude Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Prelude Capital Management sold 44,284 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $786K.
Prelude Capital Management first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 11 quarters.
Prelude Capital Management's Endocyte, Inc. Common Stock position peaked at $786K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.